StockNews.AISignal intelligence
Amedisys, Inc. · NASDAQ · Healthcare
Browse public AMED signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Justice Department opposes UnitedHealth's $3.3B Amedisys acquisition, citing competition concerns. The lawsuit may delay or block improvements in home health services.
View signal analysisDOJ and states sue to block UnitedHealth's $3.3 billion Amedisys acquisition. Concerns over reduced competition in home health services market.
View signal analysisU.S. Justice Department plans to block UnitedHealth's $3.3B bid for Amedisys. The block aims to protect competition in home health services market.
View signal analysisAmedisys reported $591.19 million in revenue, up 6.9% year-over-year. EPS of $1.32 exceeded estimates, showing an 8.20% surprise. Home health revenue increased 7.9%, surpassing analyst expectations. Recent stock performance shows Amedisys up 6.1% over the past month. Zacks Rank #3 indicates neutral performance compared to the broader market.
View signal analysisAmedisys reported earnings of $1.32, beating estimates of $1.22. Quarterly revenue reached $591.19 million, exceeding expectations by 2.05%. Management commentary on earnings will influence stock price movements. Estimates for future earnings are mixed, indicating potential volatility. Amedisys ranks #3 (Hold) with likely in-line performance.
View signal analysis- Amedisys reported adjusted earnings per share of 94 cents in Q4 2023, missing estimates. - Net service revenues for 2023 were $2.24 billion, up 0.6% year over year. - Amedisys exited 2023 with cash and cash equivalents of $126.5 million. - Price Impact Rating: Bearish - Impact Horizon Rating: Short-term - Type: Earnings
View signal analysis